Haleon has added a line of products to its well-established Panadol portfolio in the UK under new sub-brand Panmigrol.
Haleon Launches Panadol Sub-Brand For UK Migraine Sufferers
Available in UK pharmacies and supermarkets, Panmigrol’s “triple-action formulation” provides more effective migraine relief than standard ibuprofen or sumatriptan tablets, manufacturer Haleon claims.
More from United Kingdom
More from Innovation & IP
• By
Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.
• By
Advercheck managing director James Walmsley talks to HBW Insight about the challenges facing consumer health companies today as they move away from the prescription medicines sector and its pipeline of switchable ingredients towards self-care and prevention.
• By
Start-ups and individuals working on innovative consumer health concepts, in categories such as pain relief and dietary supplements, have the opportunity to access Haleon's resources and expertise to make their ideas a reality.